Merck, Moderna begin late-stage study of mRNA cancer vaccine

FILE PHOTO: Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) - Merck, along with its partner Moderna, began a late-stage study to evaluate their experimental mRNA-based cancer vaccine in combination with cancer therapy Keytruda, the companies said on Wednesday.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)